Present Algorithms and Future Treatments for Alzheimer’s Disease

Manuscript Number: 

18-0903R1

Author(s): 
Anna Burke, George T. Grossberg, Pierre N. Tariot, Gary Tong

Disclosures

Anna Burke

  • Consulting Fees:
    Eli Lilly as an adviser and lecture bureau member

George T. Grossberg

  • Consulting Fees:
    Consultant: Acadia, Alkahest, Allergan, Avanir, BioxCel, Genentech, Lundbeck, Novartis, Otsuka, Roche, Takeda Safety/Data Monitoring Committees: EryDel, Intracellular Therapeutics, Newron
    Lecture Fees:
    Acadia
    Grants
    • Agency: 
      Genentech/Roche
    • Agency: 
      NIA

Pierre N. Tariot

  • Consulting Fees:
    Personal fees from AbbVie, AC Immune, Acadia, Auspex, Boehringer Ingelheim, Chase Pharmaceuticals, Corium, Eisai, GliaCure, INSYS Therapeutics, Pfizer, T3D, AstraZeneca, Avanir, Biogen, Eli Lilly, H. Lundbeck A/S, Merck and Company, Roche, Takeda
    Equity:
    Adamas
    Patents/Royalties
    U.S. Patent # 11/632,747, “Biomarkers of Neurodegenerative disease.” Contributor to a patent owned by the University of Rochester
    Grants
    • Agency: 
      AstraZeneca
    • Agency: 
      Avanir
    • Agency: 
      Biogen
    • Agency: 
      Eli Lilly
    • Agency: 
      H. Lundbeck A/S
    • Agency: 
      Merck and Company
    • Agency: 
      Roche
    • Agency: 
      Takeda
    • Agency: 
      Amgen
    • Agency: 
      Avid
    • Agency: 
      GE Healthcare
    • Agency: 
      Genentech
    • Agency: 
      Novartis
    • Agency: 
      National Institute on Aging
    • Agency: 
      Arizona Department of Health Services

Gary Tong

  • Sponsors:
    Lundbeck